Abstract :

Background: Thyrotoxicosis is characterized by excessively high tissue thyroid hormone levels. Untreated or inadequately managed thyrotoxicosis can lead to various complications. Understanding factors influencing the time to achieve thyroid function normalization is essential for improving treatment outcomes and patient care.

Objectives: This study aimed to assess the median time to normalization of thyroid function tests and identify factors associated with delayed euthyroidism among thyrotoxic patients attending the Endocrine Clinic at St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia, in 2023.

Methods: A hospital-based retrospective cohort study was conducted involving 181 patients diagnosed with thyrotoxicosis who attended the adult Endocrine Clinic from April 2023 to January 2024. Data were collected using a structured questionnaire and entered into EpiData version 7.1, then exported to STATA version 15 for analysis. Descriptive statistics summarized continuous variables as mean ± SD or median with interquartile range, and categorical variables as frequencies and percentages. The association between independent variables and time to euthyroidism was analyzed using Cox proportional hazards regression, with the log-rank test employed to compare median times across groups. Adjusted hazard ratios (AHR) with 95% confidence intervals (CI) were reported to quantify the strength of associations.

Results: Approximately 61% of patients achieved euthyroidism, with a median time of 7 months (Interquartile Range: 3–13 months). Factors significantly associated with delayed normalization included use of Propylthiouracil (AHR = 0.33; 95% CI: 0.12–0.89), poor medication adherence (AHR = 0.24; 95% CI: 0.13–0.42), higher baseline pulse rate (AHR = 0.97; 95% CI: 0.95–0.99), and elevated baseline free thyroxin levels (AHR = 0.99; 95% CI: 0.98–0.995).

Conclusion: Although more than half of the patients attained euthyroidism, the process took longer than expected. High baseline FT4 levels, elevated pulse rate, non-adherence to medication, and the use of PTU as the anti-thyroid drug delayed the achievement of euthyroidism. Patients with thyrotoxicosis require attentive and continuous monitoring until thyroid function normalizes to prevent complications.

---

Keywords :

Ethiopia, Euthyrodism, Survival analysis, Thyrotoxicosis

---

References :

1. Kopp, P. (2018). Thyrotoxicosis. The New England Journal of Medicine, 379(1), 63–73. https://doi.org/10.1056/NEJMra1800699
2. World Health Organization, UNICEF, & ICCIDD. (2013). Assessment of iodine deficiency disorders and monitoring their elimination. WHO Document Production Services.
3. López, J. E., et al. (2017). Epidemiology of hyperthyroidism in Latin America: A systematic review. Thyroid Research, 10, 16. https://doi.org/10.1186/s13044-017-0082-4
4. Dessie, G., et al. (2019). Prevalence of goiter among children in Ethiopia and associated factors: A systematic review and meta-analysis. BMC Public Health, 19, 1507. https://doi.org/10.1186/s12889-019-7852-9
5. Tadesse, T., et al. (2016). Thyroid disorders in Ethiopia: Prevalence and diagnostic challenges. Ethiopian Medical Journal, 54(2), 87–92.
6. Ross, D. S., et al. (2016). American Thyroid Association statement on management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 26(10), 1343–1421. https://doi.org/10.1089/thy.2016.0229
7. Muller, M., & Tabet, A. (2018). Challenges in the management of hyperthyroidism in resource-limited settings. Endocrine, 62(3), 687–695. https://doi.org/10.1007/s12020-017-1394-2
8. Klein, I., & Danzi, S. (2007). Thyroid disease and the heart. Circulation, 116(15), 1725–1735. https://doi.org/10.1161/CIRCULATIONAHA.106.678326
9. Abebe, M., et al. (2020). Knowledge, attitude, and practice towards iodine deficiency and goiter among Ethiopian communities. International Journal of Endocrinology, 2020, Article 7297853. https://doi.org/10.1155/2020/7297853
10. Kebede, A., et al. (2018). Medication adherence among Ethiopian patients on antithyroid drugs. BMC Endocrine Disorders, 18, 63. https://doi.org/10.1186/s12902-018-0282-7
11. Gebreyohannes, E. A., Ayele, E. M., Tesfaye, S. A., et al. (2019). Normalization of thyroid function tests among thyrotoxicosis patients attending a university hospital in North-West Ethiopia. Thyroid Research. https://doi.org/10.1186/s13044-019-0067-6
12. Maldey, H., Tadesse, S., Alem, A. Z., et al. (2021). Time to euthyroidism and its determinants among thyrotoxicosis patients on anti-thyroid drug who attend medical and ambulatory clinics of South Tigrai General Hospitals. Therapeutics and Clinical Risk Management, 17, 1145–1155. https://doi.org/10.2147/TCRM.S324031
13. Akbar, D. H., Mushtaq, M. A., & Al-Sheikh, A. A. (2000). Etiology and outcome of thyrotoxicosis at a university hospital. Saudi Medical Journal, 21(6), 553–556.
14. Mohlin, E., Filipsson Nyström, H., & Eliasson, M. (2013). Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010. European Journal of Endocrinology, 169(6), 749–757. https://doi.org/10.1530/EJE-13-0366
15. Cooper, D. S. (1985). Propylthiouracil levels in hyperthyroid patients unresponsive to large doses: Evidence of poor patient compliance. Annals of Internal Medicine, 102(2), 169–172. https://doi.org/10.7326/0003-4819-102-2-169
16. Cooper, D. S., et al. (1999). Outcome of treatment of hyperthyroidism. Clinical Endocrinology (Oxford), 51(2), 217–222. https://doi.org/10.1046/j.1365-2265.1999.00745.x
17. Martin, S., Sirbu, A., Albu, A., Barbu, C. B., Florea, S., Boscaiu, V., & Fica, S. (2013). The time to thyroid-stimulating hormone recovery during medical treatment in Graves’ disease and autonomous hyperthyroidism. Acta Endocrinologica (Buc), 9(3), 405–418. https://doi.org/10.4183/aeb.2013.405
18. Pearce, S. H. S., Brabant, G., Duntas, L. H., et al. (2023). Unveiling risk factors for treatment failure in patients with Graves’ disease. Endocrinology and Metabolism (Seoul), 38(2), 165–174. https://doi.org/10.3803/EnM.2023.2569